A. Antón Torres

1.7k total citations
33 papers, 525 citations indexed

About

A. Antón Torres is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, A. Antón Torres has authored 33 papers receiving a total of 525 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in A. Antón Torres's work include HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Treatment and Pharmacology (7 papers). A. Antón Torres is often cited by papers focused on HER2/EGFR in Cancer Research (8 papers), Advanced Breast Cancer Therapies (7 papers) and Cancer Treatment and Pharmacology (7 papers). A. Antón Torres collaborates with scholars based in Spain, United Kingdom and Germany. A. Antón Torres's co-authors include Roberto Pazo-Cid, Francesco Carpagnano, Á. Artal, J.-Y. Douillard, R. Rosell, Teresa Puértolas, María Álvarez, Juan Lao, Claire Barton and Peter Button and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

A. Antón Torres

30 papers receiving 510 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Antón Torres Spain	8	301	190	88	76	71	33	525
Floris M Wachters Netherlands	10	306 1.0×	309 1.6×	76 0.9×	191 2.5×	44 0.6×	16	522
M. Decatris United Kingdom	12	240 0.8×	116 0.6×	72 0.8×	146 1.9×	52 0.7×	19	505
Neil Carleton United States	15	218 0.7×	127 0.7×	140 1.6×	135 1.8×	31 0.4×	38	586
Karel Cwiertka Czechia	10	247 0.8×	123 0.6×	108 1.2×	115 1.5×	35 0.5×	45	436
Danae Hamouda United States	11	230 0.8×	67 0.4×	54 0.6×	156 2.1×	29 0.4×	33	460
Carlos Alemany United States	15	411 1.4×	143 0.8×	61 0.7×	203 2.7×	36 0.5×	40	671
Sergio Vázquez‐Estévez Spain	15	233 0.8×	212 1.1×	97 1.1×	192 2.5×	52 0.7×	76	585
Esther Tahover Israel	11	359 1.2×	97 0.5×	194 2.2×	195 2.6×	137 1.9×	21	720
David A. Mahvi United States	10	294 1.0×	108 0.6×	84 1.0×	215 2.8×	42 0.6×	26	700

Countries citing papers authored by A. Antón Torres

Since Specialization

Citations

This map shows the geographic impact of A. Antón Torres's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Antón Torres with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Antón Torres more than expected).

Fields of papers citing papers by A. Antón Torres

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Antón Torres. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Antón Torres. The network helps show where A. Antón Torres may publish in the future.

Co-authorship network of co-authors of A. Antón Torres

This figure shows the co-authorship network connecting the top 25 collaborators of A. Antón Torres. A scholar is included among the top collaborators of A. Antón Torres based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Antón Torres. A. Antón Torres is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sánchez-Pernaute, Andrés, L López Antoñanzas, Miguel A. Rubio, et al.. (2024). Revisional surgery for malnutrition after SADI-S: prevalence, indications, techniques and outcomes. Updates in Surgery. 76(5). 1879–1885. 2 indexed citations

Dziaková, Jana, et al.. (2024). Spanish Experience with Latero-Lateral Duodeno-Ileostomy + Sleeve Gastrectomy with Magnet Anastomosis System. Obesity Surgery. 34(9). 3569–3575. 5 indexed citations

Fuente, N., et al.. (2024). Delayed and Long-Lasting Response to 177Lu-DOTATATE in a Head and Neck Paraganglioma: Case Report and Literature Review. SHILAP Revista de lepidopterología. 17(1). 1252–1257.

Romero‐Velez, Gustavo, Kelvin Higa, Jacqués Himpens, et al.. (2024). Single Anastomosis Duodeno-Ileostomy with Sleeve Gastrectomy/Single Anastomosis Duodenal Switch (SADI-S/SADS) IFSO Position Statement—Update 2023. Obesity Surgery. 34(10). 3639–3685. 4 indexed citations

Gelmon, Karen A., PA Fasching, Suzette Delaloge, et al.. (2023). 203P Clinical effectiveness of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer (mBC) by ER expression level: Subgroup analysis from phase IIIb LUCY trial. ESMO Open. 8(1). 101392–101392. 1 indexed citations

Gianni, Luca, Chiun‐Sheng Huang, Daniel Egle, et al.. (2023). LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study. Annals of Oncology. 34. S1258–S1259. 10 indexed citations

López‐Tarruella, Sara, Raquel Andrés Conejero, M. Martín Jiménez, et al.. (2023). 114P Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies. ESMO Open. 8(1). 101338–101338. 1 indexed citations

Turner, Nicholas C., Frederik Marmé, Sung‐Bae Kim, et al.. (2023). Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.. Journal of Clinical Oncology. 41(16_suppl). 502–502. 3 indexed citations

Wuerstlein, Rachel, Peter Ellis, Filippo Montemurro, et al.. (2022). Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer. ESMO Open. 7(5). 100561–100561. 14 indexed citations

10.

Pascual, Javier, Miguel Gil‐Gil, Christoph Zielinski, et al.. (2021). CCNE1 mRNA and cyclin E1 protein expression as predictive biomarkers for efficacy of palbociclib plus fulvestrant versus capecitabine in the phase III PEARL study.. Journal of Clinical Oncology. 39(15_suppl). 1014–1014. 2 indexed citations

11.

Wuerstlein, Rachel, Peter Ellis, Filippo Montemurro, et al.. (2021). Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).. Journal of Clinical Oncology. 39(15_suppl). 1039–1039. 4 indexed citations

12.

Berton, Dominique, Susana Banerjee, Giuseppe Curigliano, et al.. (2021). Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study.. Journal of Clinical Oncology. 39(15_suppl). 2564–2564. 29 indexed citations

13.

Khosravi‐Shahi, Parham, V. Guillem Porta, Alfredo Carrato, et al.. (2017). Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. Clinical & Translational Oncology. 20(5). 613–618. 17 indexed citations

14.

Ruíz‐Borrego, Manuel, M. Martín Jiménez, A. Ruíz, et al.. (2017). Phase III evaluating the addition of fulvestrant (F) to anastrozol (A) as adjuvant therapy in postmenopausal women with hormone receptor positive HER2 negative (HR+/HER2-) early breast cancer (EBC): Results from the GEICAM/2006-10 study. Annals of Oncology. 28. v43–v43. 4 indexed citations

15.

Tabernero, Josep, Enrique Aranda, Manuel Benavides, et al.. (2017). First prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis. Annals of Oncology. 28. v36–v36. 1 indexed citations

16.

Martínez‐Trufero, Javier, et al.. (2015). Gene expression profiling and its use in adenocarcinomas of unknown primary origin: A case report. Oncology Letters. 10(4). 2657–2661. 2 indexed citations

17.

Rayson, Daniel, Thomas Suter, Christian Jackisch, et al.. (2011). Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial. Annals of Oncology. 23(7). 1780–1788. 33 indexed citations

18.

Gregorio, M.A. De, et al.. (2009). Heparinas de bajo peso molecular en la profilaxis de episodios tromboembólicos en pacientes con cáncer portadores de catéter venoso central. Medicina Clínica. 133(10). 365–370. 4 indexed citations

19.

Garrido, Pilar, Rafael Rosell, A. Antón Torres, et al.. (2005). O-033 Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) asneoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer (NSCLC) patients (P). final results of SLCG phase II trial 9901. Lung Cancer. 49. S14–S14. 1 indexed citations

20.

Douillard, J.-Y., et al.. (2005). ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. Journal of Clinical Oncology. 23(16_suppl). 7013–7013. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact